Richardson Electronics Reports Third Quarter Results; Declares Quarterly Cash Dividend

Q3 FY25 net sales increase YoY for third consecutive quarter

Richardson Electronics ended Q3 with positive operating cash flow for the fourth consecutive quarter

 Strategic asset sale of a majority of Richardson Healthcare during the quarter further strengthened the Company's balance sheet, while expected to simplify the business and improve the financial model

LAFOX, Ill., April 09, 2025 (GLOBE NEWSWIRE) -- Richardson Electronics, Ltd. (NASDAQ:RELL) today reported financial results for its third quarter ended March 1, 2025. The Company also announced that its Board of Directors declared a $0.06 per share quarterly cash dividend.

"During the third quarter, we experienced significant year-over-year growth across key segments. Semiconductor wafer fab sales surged by 139%, while Canvys sales increased 39.5%. We achieved positive operating cash flow for the fourth consecutive quarter and ended the quarter with no debt and $36.7 million in cash and equivalents. While our cash position was bolstered by $8.2 million from the Healthcare assets sale in Q3 FY2025, the Company also generated cash from its ongoing business. We believe our strong balance sheet is an important competitive advantage with our customers and supports our long-term strategies to pursue high ROI business opportunities," said Edward J. Richardson, Chairman, CEO, and President.

Mr. Richardson added, "We are encouraged by our fiscal Q3 2025 results despite the one-time $4.9 million Healthcare charge, representing the loss on sale of assets, we are encouraged by our fiscal Q3 2025 results. Excluding this charge, our non-GAAP operating income for the quarter rose to $2.2 million, up from $1.0 million last year. Moreover, this sale marks the initial step in our strategic focus to pursue higher growth, higher margin market opportunities, particularly our Green Energy Solutions segment, while navigating an extremely fluid macro environment."

Third Quarter Results

Net sales for the third quarter of fiscal 2025 were $53.8 million, a 2.7% increase from $52.4 million in the prior year's third quarter.

Year-over-year net sales growth was due to higher sales in the Power and Microwave Technologies Group (PMT) and Canvys. PMT sales increased $2.1 million, or 6.6% from the third quarter of fiscal 2024 primarily from higher demand from the Company's semiconductor wafer fab customers. Canvys sales also increased year-over-year by $2.6 million or 39.5%, reflecting improved market conditions in North America. Healthcare sales decreased by $1.0 million, or 32.3%, from lower net sales in February 2025 after the sale of the majority of Healthcare assets. GES sales decreased $2.2 million, or 19.4%, driven by lower sales of wind turbine battery modules, which are project-based and can vary by quarter.

Backlog totaled $134.1 million at the end of the third quarter of fiscal 2025 versus $142.6 million at the end of the second quarter of fiscal 2025. The sequential decrease was primarily in GES, Canvys, and Healthcare. The Company's sales pipeline remains solid; however, the timing of new orders can vary quarter-to-quarter. In addition, backlog also reflects faster turns than prior years, reflected in the simultaneous decline in inventory.

Gross margin for the third quarter was 31.0% of net sales compared to 29.5% during the third quarter of fiscal 2024. GES gross margin increased to 32.8% from 26.6% due to product mix. PMT also posted an increase in gross margin to 30.8%, compared to 28.3%, due to favorable product mix. Canvys gross margin decreased to 33.2% from 34.4% primarily due to product mix. Richardson Healthcare's gross margin declined to 15.5% from 41.6%, as a result of product mix, manufacturing under absorption and higher scrap costs.

Operating expenses were $14.5 million, compared to $14.4 million in the third quarter of fiscal 2024. The slight increase in operating expenses resulted from higher employee compensation expenses, partially offset by lower R&D, and professional service expenses.

Loss on disposal of assets of $4.9 million resulted from the sale of the majority of Healthcare assets to DirectMed Imaging on January 24, 2025. Included in the loss was $1.4 million in excess components not needed once the exclusive supply agreement for manufacturing ALTA tubes is completed; $1.1 million for intangible assets from the IMES purchase that are no longer needed; a $1.2 million margin loss on sales of ALTA tubes as detailed under the exclusive supply agreement; $0.5 million in ALTA related fixed assets that will no longer be needed after the exclusive supply agreement ends; and $0.7 million in other directly related costs. In future periods, Healthcare's financial results will no longer be a standalone segment and will be consolidated into the Company's PMT business unit. 

Operating loss was $2.7 million and non-GAAP operating income* was $2.2 million for the third quarter of fiscal 2025, compared to an operating income of $1.0 million in the prior year's third quarter. Other expense for the third quarter of fiscal 2025, including interest income and foreign exchange, was $0.3 million, compared to other expense of less than $0.1 million in the third quarter of fiscal 2024.

Income tax benefit was $1.0 million and non-GAAP income tax provision* was $0.2 million, versus an income tax provision of $0.2 million, in the prior year's third quarter.

Net loss was $2.1 million and non-GAAP net income* was $1.6 million for the third quarter of fiscal 2025, compared to a net income of $0.8 million in the third quarter of fiscal 2024. Loss per common share (diluted) was $0.15 and non-GAAP earnings per common share (diluted)* were $0.11 in the third quarter of fiscal 2025, compared to earnings per common share (diluted) of $0.05 in the third quarter of fiscal 2024.

EBITDA* for the third quarter of fiscal 2025 was a negative $2.1 million. EBITDA* after adjusting to exclude the loss on the sale of the majority of Healthcare assets (Adjusted EBITDA*) was $2.8 million, versus $2.1 million in the prior year's third quarter.

The Company improved its solid financial position and had cash and cash equivalents of $36.7 million and $28.5 million when excluding the sale of the majority of Healthcare assets, as of March 1, 2025, versus $26.6 million as of November 30, 2024. Cash generated during the third quarter of fiscal 2025 primarily related to the sale of Healthcare assets as well as a reduction in inventory and an increase in accounts payable relating to the remaining business units. The Company invested $0.5 million during the quarter in capital expenditures primarily related to its facilities and IT systems, versus $0.4 million during last year's third quarter.

Financial Summary for the Nine Months Ended March 1, 2025

Net sales for the first nine months of fiscal 2025 were $157.0 million, an increase of 5.3%, compared to net sales of $149.1 million during the first nine months of fiscal 2024. Sales increased by $3.6 million or 3.7% for PMT, $4.8 million or 26.0% for GES, partially offset by a decrease of $0.4 million or 4.9% for Healthcare and a decrease of $0.1 million or 0.4% for Canvys.

Gross profit increased to $48.4 million during the first nine months of fiscal 2025, compared to $45.2 million during the first nine months of fiscal 2024. As a percentage of net sales, gross margin was 30.8% of net sales during the first nine months of fiscal 2025, compared to 30.3% during the first nine months of fiscal 2024 primarily due to product mix.

Operating expenses increased to $46.6 million for the first nine months of fiscal 2025, compared to $44.7 million for the first nine months of fiscal 2024. The increase in operating expenses resulted from higher employee compensation expenses, partially offset by lower R&D expenses.

Loss on disposal of assets of $4.9 million resulted from the sale of the majority of Healthcare assets to DirectMed Imaging on January 24, 2025.

Operating loss was $3.1 million and non-GAAP operating income* was $1.8 million during the first nine months of fiscal 2025, compared to operating income of $0.5 million during the first nine months of fiscal 2024.

Other expense for the first nine months of fiscal 2025, including interest income and foreign exchange, was $0.4 million, compared to other expense of $0.2 million in the first nine months of fiscal 2024.

The income tax benefit was $1.3 million and the non-GAAP income tax provision* was $1,000 for the first nine months of fiscal 2025 compared to an income tax provision of $0.1 million during the first nine months of fiscal 2024.

Net loss was $2.2 million and non-GAAP net income* was $1.4 million for the first nine months of fiscal 2025, versus a net income of $0.2 million during the first nine months of fiscal 2024. Net loss per common share (diluted) was $0.16 and non-GAAP earnings per common share* was $0.10 for the first nine months of fiscal 2025 compared to $0.01 earnings per common share (diluted) for the first nine months of fiscal 2024.

EBITDA* for the first nine months of fiscal 2025 was a negative $0.5 million. EBITDA* after adjusting to exclude the loss on the sale of Healthcare assets (Adjusted EBITDA*) was $4.5 million, versus $3.5 million in the prior year's first nine months.

* Please refer to Unaudited Reconciliation between GAAP and non-GAAP Financial Measures below for a reconciliation of non-GAAP items to the comparable GAAP measures.

CASH DIVIDEND DECLARED

The Board of Directors of Richardson Electronics declared a $0.06 quarterly cash dividend per share to holders of common stock and a $0.054 cash dividend per share to holders of Class B common stock. The dividend will be payable on May 28, 2025, to common stockholders of record as of May 9, 2025.

NON-GAAP FINANCIAL MEASURES

In addition to financial measures ("GAAP financial measures") prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), we have included financial measures in this press release that are not defined by or calculated in accordance with GAAP (collectively, "non-GAAP financial measures"). For each of the non-GAAP financial measures referenced in this release, we are providing below a reconciliation of differences between the non-GAAP financial measure and the most directly comparable GAAP financial measure. We also provide an explanation of why the Company believes these non-GAAP financial measures provide useful information to investors, and any additional material purposes for which our management or Board of Directors use these non-GAAP financial measures.

Non-GAAP Operating Income: Non-GAAP operating income is GAAP operating income (loss), adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of non-GAAP Operating Income for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

(Loss) income from operations

 

$

(2,743

)

 

$

1,006

 

 

$

(3,094

)

 

$

462

 

Disposal of Healthcare assets

 

 

4,916

 

 

 

—

 

 

 

4,916

 

 

 

—

 

Non-GAAP Operating Income

 

$

2,173

 

 

$

1,006

 

 

$

1,822

 

 

$

462

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Income Before Taxes: Non-GAAP Income Before Taxes is income before taxes, adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of non-GAAP Income Before Taxes for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

(Loss) income before income taxes

 

$

(3,088

)

 

$

979

 

 

$

(3,495

)

 

$

296

 

Disposal of Healthcare assets

 

 

4,916

 

 

 

—

 

 

 

4,916

 

 

 

—

 

Non-GAAP Income Before Taxes

 

$

1,828

 

 

$

979

 

 

$

1,421

 

 

$

296

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Income Tax Benefit or Expense: Non-GAAP Income Tax Benefit or Expense is income tax (benefit) provision, adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of non-GAAP Income Tax (Benefit) Expense for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

Income tax (benefit) provision

 

$

(1,031

)

 

$

229

 

 

$

(1,277

)

 

$

116

 

Disposal of Healthcare assets

 

 

1,278

 

 

 

—

 

 

 

1,278

 

 

 

—

 

Non-GAAP Income Tax Benefit or Expense

 

$

247

 

 

$

229

 

 

$

1

 

 

$

116

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Net Income: Non-GAAP Net Income is net (loss) income, adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of non-GAAP Net Income for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

Net (loss) income

 

$

(2,057

)

 

$

750

 

 

$

(2,218

)

 

$

180

 

Disposal of Healthcare assets

 

 

3,638

 

 

 

—

 

 

 

3,638

 

 

 

—

 

Non-GAAP Net Income

 

$

1,581

 

 

$

750

 

 

$

1,420

 

 

$

180

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP Earnings Per Common Share (Diluted): Non-GAAP Earnings Per Common Share (Diluted) is net (loss) income per share (diluted), adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of non-GAAP Earnings Per Common Share (diluted) for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

Net (loss) income per share (diluted)

 

$

(0.15

)

 

$

0.05

 

 

$

(0.16

)

 

$

0.01

 

Loss on sale of Healthcare assets

 

 

0.26

 

 

 

—

 

 

 

0.26

 

 

 

—

 

Non-GAAP Earnings Per Common Share (Diluted)

 

$

0.11

 

 

$

0.05

 

 

$

0.10

 

 

$

0.01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA: EBITDA is net (loss) income, plus income tax expense (benefit) and depreciation and amortization expense. The following table represents the Company's calculation of EBITDA for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

Net (loss) income

 

$

(2,057

)

 

$

750

 

 

$

(2,218

)

 

$

180

 

Income tax expense (benefit)

 

 

(1,031

)

 

 

229

 

 

 

(1,277

)

 

 

116

 

Depreciation & amortization

 

 

978

 

 

 

1,104

 

 

 

3,037

 

 

 

3,218

 

EBITDA

 

$

(2,110

)

 

$

2,083

 

 

$

(458

)

 

$

3,514

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA: Adjusted EBITDA is EBITDA (a non-GAAP financial measure defined and calculated in accordance with the above), adjusted to exclude a one-time loss on the sale of assets of the Company's Healthcare business. The following table represents the Company's calculation of Adjusted EBITDA for the periods presented and a reconciliation to the most directly comparable GAAP financial measure:

 

 

Unaudited ($ in thousands)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

March 1, 2025

 

 

March 2, 2024

 

 

March 1, 2025

 

 

March 2, 2024

 

Net (loss) income

 

$

(2,057

)

 

$

750

 

 

$

(2,218

)

 

$

180

 

Income tax expense (benefit)

 

 

(1,031

)

 

 

229

 

 

 

(1,277

)

 

 

116

 

Depreciation & amortization

 

 

978

 

 

 

1,104

 

 

 

3,037

 

 

 

3,218

 

EBITDA

 

$

(2,110

)

 

$

2,083

 

 

$

(458

)

 

$

3,514

 

Disposal of Healthcare assets

 

 

4,916

 

 

 

—

 

 

$

4,916

 

 

 

—

 

Adjusted EBITDA

 

$

2,806

 

 

$

2,083

 

 

$

4,458

 

 

$

3,514